United Therapeutics: Tyvaso Study Data Represents a new $5.4 Billion Opportunity – the Stock Reaches a new all-Time High!

United Therapeutics (UTHR) aims to reach a total revenue of $16 billion by 2030 through the treatment of rare and life-threatening lung diseases as well as through initial revenues from manufactured transplantable organs. The core product Tyvaso (Treprostinil) is currently approved for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with approximately 80,000 patients. The approval of the competing product Yutrepia in May has so far had no significant negative impact, and Insmed...